Tarlatamab (AMG-757) is a bispecific T cell engager (BiTE) antibody targeting DLL3 and CD3, with human DLL3 and CD3 KD = 0.64 nM/14.9 nM, for use in immuno-oncology therapy of small cell lung cancer (SCLC).

CD3 (human):14.9 nM (Kd), DLL3 (human):0.64 nM （Kd)

Tarlatamab (0-10 nM; 48 h) exhibits specific cytotoxicity toward DLL3-expressing SCLC cell lines [1].
Tarlatamab (0-10 nM; 4-72 h) increases granzyme B levels and cytotoxicity in a time-dependent manner, with maximal signaling observed at 48 h. T-cell activation or inflammatory markers CD69, CD71, PD-1, and PD-L1 (37-39) were upregulated[1].

Tarlatamab (3 mg/kg; intraperitoneal administration; once weekly; for three consecutive weeks) demonstrated tumor regression in a small cell lung cancer (SCLC) mouse model [1].
Tarlatamab (12 μg/kg; intraperitoneal administration; single dose) exhibited a mean half-life of 234 hours, mean clearance of 0.487 mL/hour/kg, and steady-state volume of distribution of 146 mL/kg in non-human primates (NHPs) [1].

Human

Monoclonal

Unconjugated